Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
| ▸ | GPR17 | Q13304 | 4/20 | 0.36 |
| ▸ | MCL1 | Q07820 | 5/20 | 0.35 |
| ▸ | BCL2 | P10415 | 2/20 | 0.35 |
| ▸ | DCTPP1 | Q9H773 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 2/20 | 0.33 |
| ▸ | THRA | P10827 | 1/20 | 0.33 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.33 |
| ▸ | PIK3C2B | O00750 | 2/20 | 0.33 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6489388 | 0.92 | GABRA1 (0.36) | PPARGDCTPP1THRBTHRAPLA2G2A | |
| SCHEMBL6491906 | 0.88 | PPARG (0.45) | PPARGGPR17MCL1ALOX5APKDM4E | |
| SCHEMBL6499907 | 0.86 | PPARG (0.39) | PPARGDCTPP1PIK3C2BNPC1ALDH1A1 | |
| SCHEMBL6497985 | 0.86 | PPARG (0.36) | PPARGMCL1DCTPP1THRBTHRA | |
| SCHEMBL6490173 | 0.85 | RARB (0.47) | PPARGDCTPP1 | |
| SCHEMBL6497730 | 0.84 | PPARG (0.44) | PPARGMCL1DCTPP1PLA2G2A | |
| SCHEMBL6497678 | 0.84 | PTPN11 (0.46) | PPARG | |
| SCHEMBL6488387 | 0.83 | PIK3C2B (0.37) | DCTPP1PIK3C2BALOX5AP | |
| SCHEMBL6488344 | 0.82 | MCL1 (0.47) | PPARGGPR17MCL1THRBTHRA | |
| SCHEMBL6487238 | 0.81 | PPARG (0.35) | PPARGDCTPP1THRBTHRAPLA2G2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050014812-A1 | Benzimidazole compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014812-A1 | Benzimidazole compounds | SLC5A1, SLC5A2, G6PD | PPARG 233/4885GPR17 813/4885MCL1 806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.